App Update from 14.4.2021
Vaccine Name Changed
Astra-Zeneca vaccine now called Vaxzevria
The EMA approved the vaccine brand name on 25 March 2021. The original name was ChAdOx1. In the spring of 2020, AstraZeneca christened the vaccine AZD1222. It was approved on 29/01/2021 under the name ‘COVID-19 Vaccine AstraZeneca’. The company told the Deutsche Presse-Agentur (dpa) that the switch to Vaxzevria had been planned for many months.
Notice Of Thromboses and Deaths
Possible vaccination complications and warnings added
Following several reports of thrombosis in combination with thrombocytopenia after vaccination with Vaxzevria, the Robert Koch Institute (RKI) supplemented its information leaflet on 1 April 2021. A possible vaccination complication is now mentioned: 4 to 16 days after vaccination with Vaxzevria, thromboses combined with thrombocytopenia, sometimes also with bleeding, have been observed in very rare cases. Also mentioned are some severe cases of sinus or mesenteric vein thrombosis, along with increased clotting activity or bleeding throughout the body. According to the RKI, the majority of these cases occurred in people under the age of 60. Some of the cases ended fatally or in permanent damage. Another new feature is a list of warning signs for which vaccinated people should immediately consult a doctor.
Only for 60 and Up
New age recommendation from the STIKO
The Standing Committee on Vaccination at the RKI (STIKO) now only recommends Vaxzevria® for people who are 60 years of age or older. However, vaccination with Vaxzevria is still possible for people under 60 if they make this decision with their doctor. For people over 60 who received a first vaccination with Vaxzevria, the STIKO also recommends Vaxzevria for the second vaccination. According to the STIKO, people under 60 who have received a first vaccination with Vaxzevria should get an mRNA vaccine as their second vaccination 12 weeks later.